Certain conditions are established as risk factors for community-acquired pneumonia. There are a number of other conditions that may also be risk factors, but information on these is limited.
INTRODUCTION
Community-acquired pneumonia is a serious condition, which affects annually up to 11 per 1000 adults, 1 and up to 40 per 1000 of children. 2 Of these, almost half require hospital admission. Streptococcus pneumoniae is the commonest cause of communityacquired pneumonia and can be fatal in up to 20% of cases. 3 While pneumonia can affect any age group, at most risk are adults aged ≥65 years, and infants and young children, who do not have a fully developed immune system. Patients at risk include those with splenic dysfunction, 4 cochlear implants or cerebrospinal fluid shunts, 3 chronic cardiovascular disease, chronic pulmonary disease, diabetes, 5 chronic liver disease, [6] [7] [8] and chronic renal failure, 5, 9 as well as those with HIV and AIDS. 10, 11 The 23-valent pneumococcal immunisation has been recommended since 1992 for individuals at high risk of invasive pneumococcal disease, and in 2003 the recommendation was extended to include all people aged ≥65 years. Pneumococcal vaccination rates have increased over time as a consequence. 12 However, there might be other patients who are at increased risk of pneumonia with conditions that are not included in the vaccine guidelines. Equally, some of those in established risk groups included in the guidelines may not actually be at high risk, since evidence is limited for some of the specified risk groups. Patients with rheumatoid arthritis, for example, are not included in the guidance although they seem to be susceptible to pneumococcal disease. 13, 14 Pneumonia is also the most common cause of death in patients with acute stroke, 15 and it occurs more frequently than expected in dementia patients, 7, 16 and in patients with solid cancers. 11, 17, 18 Given the uncertainty regarding the effectiveness of pneumococcal vaccination, 19 and in the presence of increasing morbidity due to pneumonia, GPs need to be able to identify and closely monitor those patients at highest risk of pneumonia. For example, such patients might benefit from earlier intervention with antibiotics when they present to their GP with a chest infection. 20 Better understanding about high-risk groups for pneumonia could also help inform future development of an effective vaccine to prevent pneumonia.
The main aim of this study is to identify additional independent risk factors for community-acquired pneumonia, which could potentially be used in clinical practice to guide treatment decisions.
METHOD

Study design and setting
A nested case-control study was conducted using general practices in the UK contributing to the QRESEARCH database (version 11, downloaded August 2006). The study period was the 10 years between 1 January 1996 and 31 December 2005.
Study population
An open cohort of patients registered at any time between 1 January 1996 and 31 December 2005, excluding temporary residents, was identified. For each patient, a left censor date was determined, which was the latest of the start of the study: 1 January 1996; the date of patient registration with the practice; or the date of the installation of the EMIS computer system. A right censor date was also defined, which was the earliest of the following: date of diagnosis of the outcome of interest; date of death; date of leaving the practice; date of the latest download of data; or 31 December 2005.
Cases of pneumonia
Patients with an incident diagnosis of pneumonia were identified -that is, patients with a first diagnosis during the 10-year study period (a list of diagnostic codes is available from the authors). Patients with a postmortem diagnosis were included as cases, but patients with a diagnosis prior to their entry into the cohort were excluded.
Selection of controls
Each case was matched to five controls who were alive and registered with the practice where the case was registered at the time of diagnosis of each case. Controls were matched on age at index date (to within 1 year), sex, practice, and calendar time. Selection of controls was made without replacement. Controls were allocated an index date, which was the date on which their matched case was first diagnosed with pneumonia.
Patients aged >5 years were included in the analysis if they had at least 5 years of electronic health records available. Children ≤5 years old were included in the analysis if they had complete health records since their birth. This was to ensure the data for vaccinations, prescriptions, and morbidity were as complete as possible over a 5-year period.
Risk groups from current guidance
'Established risk factors' were based on those patients identified as being at high risk of invasive pneumococcal disease according to the Chief Medical Officer's guidance for 2006. 21 The following diseases were included: diabetes, chronic heart disease, chronic renal disease, chronic respiratory disease, asplenia, cerebrospinal fluid shunt, chronic liver disease, sickle cell or coeliac disease, cochlear implant, HIV/AIDS, and immunosuppression. Immunosuppression did not include patients already identified as being at high risk due to the other diseases in the list.
In addition, the risk was estimated in patients with chronic heart disease but without ischaemic heart disease, in patients with treated asthma, and in patients with asthma but no evidence of treatment ('untreated asthma'). Asthma treatment was defined as at least one prescription for a β agonist and/or at least one inhaled steroid within the preceding 12 months.
New potential risk groups
The risk of pneumonia was determined in patients with other morbidities including the following: stroke or transient ischaemic attack, rheumatoid arthritis, Parkinson's disease, five common cancers (breast, colon, gastric, lung, prostate), multiple sclerosis, dementia, osteoporosis, and osteoarthritis.
These diseases were chosen either because they limit the mobility of patients, which might in turn increase the risk of pneumonia, or because they tend to be associated with immunosuppression.
Patients were considered to be in a current or new disease risk group if they had an appropriate Read code group in their electronic health record before the date of diagnosis of pneumonia, for cases, or before the matched index date, for controls.
Statistical analysis
All the available cases on the QRESEARCH database who met the inclusion criteria were used, in order to maximise the power of the study. Five matched controls were used per patient, since using more controls than this does not tend to increase the study power. 22 In order to detect an odds ratio (OR) of 1.50 (which was predefined as being clinically important) at 1% significance with 80% power for a condition that occurs in 0.5% of controls, a sample size of 13 500 cases and 67 500 controls would be needed.
Conditional Key analyses were repeated, restricted to cases and controls where the index date was prior to 2003 (the year in which pneumococcal vaccine was recommended to all patients aged ≥65 years), and to cases and controls with at least 10 full years of electronic prescribing records available. The analyses were also repeated restricted to cases with lobar and pneumococcal pneumonia and their controls, as those diagnoses were most likely made on hospital discharge. STATA (version 10) was used for all the analyses. Given the large number of comparisons being undertaken, a P value of 0.01 or less was considered statistically significant. A priori, an OR≥1.5 was considered to be clinically important.
Missing data for smoking status and Townsend deprivation score were analysed as a separate category. As records for children younger than 15 years hardly contained information about smoking status, they were assumed to be non-smokers. The analyses were also repeated considering smoking status in children as not recorded.
RESULTS
Incidence rates of pneumonia
There were 443 QRESEARCH practices included in the analysis. Overall there were 34 098 incident cases of pneumonia arising from 29 605 328 patient-years, giving an overall incidence rate of 115 per 100 000 patient-years.
The incidence of pneumonia varied by year and age group, approximately doubling between 1996 and 2005 in all age groups and reaching an age-sexstandardised rate of 150 cases per 100 000 in 2005. The incidence rate was highest in patients aged ≥75 years, next highest in patients aged 0-4 years, and lowest in patients aged 15-44 years. Of all the cases of pneumonia, 25% had lobar or pneumococcal pneumonia. The distribution of specific diagnoses in all cases with pneumonia is presented in Table 1 . There were 17 172 cases with at least 5 years of prior data, and these were included in the remaining analyses. Of these 4485 (26%) had lobar or pneumococcal pneumonia. Y Vinogradova, J Hippisley-Cox and C Coupland e333 for cases to be from more deprived areas than controls. Uptake of influenza vaccination in the preceding 12 months was also marginally higher in cases than controls. Figure 1 and Table 3 show the number of cases and controls with diagnoses for diseases in the established risk groups, and in the potential new risk groups prior to the date of diagnosis of pneumonia in cases, and to the equivalent index date in controls. Almost half of the cases (46%) had been diagnosed with at least one of the diseases in the existing risk groups, compared to 29% of the controls. The unadjusted ORs for all of the current risk factor diseases were >1.5, apart from in the immunosuppressed patient group, where the unadjusted OR was 1.12 (95% CI = 1.03 to 1.21). For the new potential risk factors, the proportion of cases diagnosed with any of these diseases was significantly higher than among controls. Most of the unadjusted OR were >1.5. Among the cancer patients, Adjustment for a number of potential confounding variables tended to reduce the OR, with the exception of the immunosuppressed, multiple sclerosis, and dementia groups. The adjusted ORs for all current and potential risk groups were greater than 1.5, except for in the diabetes, immunosuppressed, and any cancer groups. The highest adjusted ORs were for multiple sclerosis, HIV/AIDS, and asplenia. (5, 6, 7, 8 ,9, ≥10) . OR = odds ratio. 
Baseline characteristics of pneumonia cases and controls
Risks of pneumonia according to disease risk groups
Online
Restricted analyses
The analyses were repeated on patients aged 5-64 years. The results were similar to those in patients of all ages. The risk of pneumonia in those with one or more current risk factor diseases and no new risk factor disease adjusted for the confounding variables was twofold increased (OR: 1.96, 95% CI = 1.82 to 2.11), and in those with one or more diseases from the potential risk factor list (excluding osteoarthritis) and not diagnosed with any of the current risk group diseases, it was 2.3-fold increased (OR: 2.32, 95% CI = 1.91 to 2.82). These results are shown in Figure 2 and (5, 6, 7, 8, 9, 10) . Table 5 shows the number of cases and controls vaccinated with pneumococcal vaccine. Only 16.4% of cases and 14.4% of controls had records of pneumococcal vaccination in the last 5 years. Among the patients with at least 10 years of medical records, the proportion of cases who had been vaccinated in the last 10 years was 18.3%, and the proportion of controls was 14.3%. Table 5 shows results from adjusted analyses for time since the last vaccination in individuals with at least 5 and 10 years of data. There was a significantly lower risk of pneumonia in patients who had been vaccinated between 15 and 365 days previously, compared with those not vaccinated in the last 5 years (OR 0.83, 95% CI = 0.76 to 0.92), but not in patients vaccinated more than 12 months earlier. Table 5 also shows the results of the analysis regarding the use of pneumococcal vaccine, but restricted to patients with lobar or pneumococcal pneumonia. The adjusted OR were similar to those for all pneumonia cases, although they were not statistically significant at the 1% significance level.
Pneumococcal vaccination
All the analyses were performed assuming missing smoking status for children aged <15 years as nonsmokers. Exactly the same results were obtained for all analyses, assuming smoking status for children as not recorded.
DISCUSSION
Summary of main findings
This is a large population-based case-control study designed to determine risk factors for communityacquired pneumonia. Overall, the study has shown that diagnoses of pneumonia are about two to three times more common in individuals in any of the specified clinical risk groups (both existing and new risk groups) than in individuals without these conditions. Similar results were obtained for subgroup analyses on patients with more specific diagnoses of lobar or pneumococcal pneumonia.
The increased risk of all-cause pneumonia among patients in existing risk groups persisted despite adjustment for the potential confounding effects of deprivation, smoking, and influenza and pneumococcal vaccination (OR: 2.29 in patients with one or more current risk factor diseases). This analysis, therefore, reinforces existing risk groups which include patients with diabetes, chronic heart disease, chronic renal disease, chronic respiratory disease, asplenia, cerebrospinal fluid shunt, chronic liver disease, sickle cell disease, coeliac disease, cochlear implant, HIV/AIDS, or immunosuppression.
The new risk groups identified in this study include patients with stroke or transient ischaemic attack, rheumatoid arthritis, Parkinson's disease, cancers, multiple sclerosis, dementia, and osteoporosis. Overall, a 2.5-fold increased risk of all-cause pneumonia was found among patients with one or more of these new risk factors, taking into account known risk factors and potential confounding variables (OR: 2.44). Patients with lung cancer and multiple sclerosis have particularly high increased risk of pneumonia, with fivefold and threefold increased risks respectively. The magnitude of these risks exceeds that observed for the majority of existing risk groups.
The study also showed some effectiveness of the pneumococcal vaccine, decreasing the risk of pneumonia by 17% (OR: 0.83, 95% CI = 0.76 to 0.92), and only if the vaccine was administrated within the year before the index date. This effect is not large and is not protective enough for the general population; therefore, taking into account other risk factors is essential in preventing pneumonia. A similar conclusion was reached in a systematic review and meta-analysis based on 22 randomised control trials showing no significant preventive effect of pneumococcal vaccination. 23 This is a unique study in the community setting looking at the effect of comorbidities on the risk of pneumonia. British Thoracic Society guidelines recognised such conditions as asplenia, sickle cell and coeliac disease, renal disease, heart disease, lung disease, liver disease, diabetes, and immunosuppression due to HIV infection; 1 and these diseases are included in the vaccine guidelines. This study has not only confirmed that patients with current risk group conditions have an increased risk of pneumonia, but has also demonstrated that there is an additional group of patients who are not recommended for pneumococcal vaccination but have an increased risk of pneumonia.
Strengths and limitations of the study
The study has several strengths. The QRESEARCH database has been validated (http://www.qresearch. org) and covers a large representative population from primary care, so the results are likely to be generalisable to the rest of the UK. As the study is based on computer-recorded prescribing and morbidity data collected prospectively, it was possible to include all eligible patients (including those who had died), thereby avoiding selection bias.
Matching of controls to cases on age, sex, calendar time, and practice removed confounding by these factors. The analysis was also adjusted for smoking, deprivation, and influenza and pneumococcal vaccinations, to minimise the potential confounding effects of these variables. In contrast to studies based on questionnaire or interview data, there is no recall bias, since information about the patient and morbidities, as well as exposure to pneumococcal vaccine, was prospectively recorded on computer before the diagnosis of pneumonia was made and so is unaffected by the pneumonia diagnosis itself. Any bias due to misclassification is likely to be minimal, because recording of clinical diagnosis and use of prescribed medications in general practice has been shown to have high levels of accuracy and completeness. 24 The study had some limitations -information on certain risk factors for pneumonia such as use of alcohol is less consistently recorded in patient electronic health records and so has not been included in the analysis. The study has, however, included liver disease, which could be viewed as a proxy for chronic alcohol use. As with all observational studies, there could be residual confounding which it is not possible to fully correct.
The increased risk of pneumonia in the previously identified and newly identified risk groups could be a reflection of consulting bias, where pneumonia is opportunistically diagnosed when patients consult for one of these conditions. However, given that pneumonia is a serious diagnosis, it is unlikely that such a diagnosis would be made by chance in a patient consulting for another reason.
The other limitation is that the diagnosis of pneumonia was recorded by a GP and quite often was not supported by chest X-ray examination. However, British Thoracic Society guidelines do not consider chest radiograph as a necessary investigation for such patients in the community, relying instead on clinical symptoms of pneumonia. 1 However, a GP's knowledge of a patient's comorbidities might alter the likelihood of making the diagnosis of pneumonia. This is a potential source of diagnostic bias which cannot be controlled for.
Comparison with existing literature
The pneumonia incidence rates have increased over time, which is consistent with trends of hospital admissions for pneumonia, 25 but contrasts with trends in incidence data reported by the Royal College of General Practitioners (RCGP), 26 which have shown a consistent decline. More detailed comparisons, however, between QRESEARCH and RCGP data show that, when similar definitions of pneumonia are used, the rates are comparable, suggesting that some of the difference is due to differences in data capture and case definition (D Fleming, personal communication, 2007) . The definitions of pneumonia in the present analyses, for example, include postmortem diagnoses and diagnoses entered retrospectively after discharge from hospital, whereas the RCGP data only include contemporaneous diagnoses made during GP consultations.
Implications for clinical practice and future research
In addition to confirming some 'established risk factors', this study has identified seven new independent risk factors for all-cause communityacquired pneumonia. The results of this study could help clinicians identify patients at higher risk of pneumonia and also help inform future vaccine development given the possible lack of efficacy of the 23-valent vaccine against pneumonia. Further research would be needed to determine whether these high-risk patient groups would benefit from early intervention with antibiotics in the event of a respiratory infection or during a flu epidemic.
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